Vicore Pharma Holding AB
VCREDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
C21 | Phase 3 | COVID-19 | - | - |
Buloxibutid | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vicore Pharma Holding AB's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Vicore Pharma Holding AB's (VCRE) pipeline across Phase 3, Phase 2. Its lead program is C21 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vicore Pharma Holding AB's next FDA catalyst?→
Vicore Pharma Holding AB's (VCRE) next tracked catalyst is a Phase 2 expected May 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VCRE biotech catalysts?→
Add VCRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vicore Pharma Holding AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.